ERS International Congress 2023: highlights from the Thoracic Oncology Assembly

Journal article

Lung cancer is the leading cause of cancer mortality in the world. It greatly affects the patients' quality of life, and is thus a challenge for the daily practice in respiratory medicine. Advances in the genetic knowledge of thoracic tumours' mutational landscape, and the development of targeted therapies and immune checkpoint inhibitors, have led to a paradigm shift in the treatment of lung cancer and pleural mesothelioma. During the 2023 European Respiratory Society Congress in Milan, Italy, experts from all over the world presented their high-quality research and reviewed best clinical practices. Lung cancer screening, management of early stages of lung cancer, application of artificial intelligence and biomarkers were discussed and they will be summarised here.

Authors: Catarata, MJ; Creamer, AW; Dias, M; Toland, S; Chaabouni, M

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: European Respiratory Society
• Journal: ERJ Open Research
• Volume: 10
• Issue: 1
• Pages: 860-2023
• Publication date: 2024-01-01
• DOI: 10.1183/23120541.00860-2023
• ISSN: 2312-0541
• Pmid: 38410708
• Language: English